Lipid-modified immune response modifiers

A compound of the following Formula I:

• wherein:
• R1 has the formula alkylene-L-R1-1, alkenylene-L-R1-1, or alkynylene-L-R1-1, wherein:
• the alkylene, alkenylene, and alkynylene groups are optionally interrupted with one or more —O— groups;
• L is a bond or a functional linking group selected from the group consisting of —NH—S(O)2—, —NH—C(O)—, —NH—C(S)—, —NH—S(O)2—NR3—, —NH—C(O)—NR3—, —NH—C(S)—NR3—, —NH—C(O)—O—, —O—, —S—, and —S(O)2—;
• and
• R1-1 is a linear or branched aliphatic group having at least 11 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds;
• R″ is selected from the group consisting of:
• hydrogen;
• alkyl;
• alkenyl;
• aryl;
• heteroaryl;
• heterocyclyl;
• alkylene-Y-alkyl;
• alkylene-Y-alkenyl;
• alkylene-Y-aryl;
• and
• alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
• —OH;
• halogen;
• —N(R4)2;
• —C(O)—C1-10alkyl;
• —C(O)—O—C1-10alkyl;
• —N3;
• aryl;
• heteroaryl;
• heterocyclyl;
• —C(O)-aryl;
• and
• —C(O)-heteroaryl;
• wherein:
• Y is —O— or —S(O)0-2—;
• and each R4 is independently selected from the group consisting of hydrogen, C1-10alkyl, and C2-10alkenyl;
• RA and RB are each independently selected from the group consisting of:
• hydrogen,
• halogen,
• alkyl,
• alkenyl,
• alkoxy,
• alkylthio, and
• —N(R3)2;
• or when taken together, RA and RB form a fused aryl ring or heteroaryl ring containing one heteroatom selected from the group consisting of N and S wherein the aryl or heteroaryl ring is unsubstituted or substituted by one or more R groups;
• or when taken together, RA and RB form a fused 5- to 7-membered saturated ring, optionally containing one heteroatom selected from the group consisting of N and S, and unsubstituted or substituted by one or more R groups;
• each R is independently selected from the group consisting of
• halogen,
• hydroxy,
• alkyl,
• alkenyl,
• haloalkyl,
• alkoxy,
• alkylthio, and
• —N(R3)2;
• and
• each R3 is independently selected from the group consisting of hydrogen and alkyl;
• with the proviso that when L is —NH—S(O)2— and RA and RB join to form an unsubstituted benzene ring, R1-1 is a linear or branched aliphatic group having greater than 16 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds;
• and with the further proviso that when L is —NH—C(O)— and RA and RB join to form an unsubstituted pyridine ring, R1-1 is a linear or branched aliphatic group having greater than 11 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds;
• or a pharmaceutically acceptable salt thereof.